<DOC>
	<DOCNO>NCT02776371</DOCNO>
	<brief_summary>Helicobacter pylorus ( H. pylorus ) infect 50 % population world ( 1 ) , especially 47-66 % China .</brief_summary>
	<brief_title>Modified Non-clarithromycin Triple Therapy Eradicating Helicobacter Pylori</brief_title>
	<detailed_description />
	<mesh_term>Esomeprazole</mesh_term>
	<mesh_term>Tinidazole</mesh_term>
	<mesh_term>Amoxicillin</mesh_term>
	<criteria>Patients intend undergo upper endoscopy purpose volunteer write inform consent . negative rapid urease test ( RUT ) previous standard eradication therapy H. pylorus ; history esophagectomy gastrectomy ; gastrointestinal malignancy ; contraindication allergic study drug ; user take medicine may affect result study within 4 week ( e.g. , protonpump inhibitor , H2receptor antagonists , bismuth antibiotic etc . ) ; cardiopulmonary , hepatic renal insufficiency , and/or severe current disease malignancy ; pregnant lactating woman ; participant trial within past 3 month ; unwilling unable participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Helicobacter pylorus</keyword>
	<keyword>Sequential therapy</keyword>
	<keyword>Modified non-clarithromycin triple therapy</keyword>
</DOC>